Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain by Zalachoras, I. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/125235
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
METHODOLOGY ARTICLE Open Access
Antisense-mediated isoform switching of steroid
receptor coactivator-1 in the central nucleus of
the amygdala of the mouse brain
Ioannis Zalachoras1,2,4*, Gwendolynn Grootaers1, Lisa TCM van Weert1, Yves Aubert1, Suzanne R de Kreij1,
Nicole A Datson1,3, Willeke MC van Roon-Mom3, Annemieke Aartsma-Rus3 and Onno C Meijer1,2
Abstract
Background : Antisense oligonucleotide (AON)-mediated exon skipping is a powerful tool to manipulate gene
expression. In the present study we investigated the potential of exon skipping by local injection in the central
nucleus of the amygdala (CeA) of the mouse brain. As proof of principle we targeted the splicing of steroid
receptor coactivator-1 (SRC-1), a protein involved in nuclear receptor function. This nuclear receptor coregulator
exists in two splice variants (SRC-1a and SRC-1e) which display differential distribution and opposing activities in the
brain, and whose mRNAs differ in a single SRC-1e specific exon.
Methods: For proof of principle of feasibility, we used immunofluorescent stainings to study uptake by different
cell types, translocation to the nucleus and potential immunostimulatory effects at different time points after a local
injection in the CeA of the mouse brain of a control AON targeting human dystrophin with no targets in the
murine brain. To evaluate efficacy we designed an AON targeting the SRC-1e-specific exon and with qPCR analysis
we measured the expression ratio of the two splice variants.
Results: We found that AONs were taken up by corticotropin releasing hormone expressing neurons and other
cells in the CeA, and translocated into the cell nucleus. Immune responses after AON injection were comparable to
those after sterile saline injection. A successful shift of the naturally occurring SRC-1a:SRC-1e expression ratio in
favor of SRC-1a was observed, without changes in total SRC-1 expression.
Conclusions: We provide a proof of concept for local neuropharmacological use of exon skipping by manipulating
the expression ratio of the two splice variants of SRC-1, which may be used to study nuclear receptor function in
specific brain circuits. We established that exon skipping after local injection in the brain is a versatile and useful
tool for the manipulation of splice variants for numerous genes that are relevant for brain function.
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Background
Alternative splicing in the brain has gained significant at-
tention recently and may be important for a vast number
of processes [1] such as synaptic function [2] and learning
and memory [1]. Examples of alternatively spliced genes
include the D2 receptor gene [3], the corticotropin
releasing hormone (CRH) receptor genes [4] and the can-
nabinoid receptor genes [5,6]. A limitation to the study of
the roles of the various splice variants in brain function is
that very often specific ligands or inhibitors are lacking.
Furthermore, transgenic approaches may be both costly
and time consuming, and/or depend on viral delivery
which may induce immune responses [7].
Single stranded DNA or RNA antisense oligonucleo-
tides (AONs) that target RNA transcripts can be used to
manipulate gene expression in different manners. DNA:
RNA or RNA:RNA hybrids can be cleaved by RNase H
resulting in knockdown of gene expression. A similar
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effect can be achieved via steric hindrance of the riboso-
mal complex by an AON resulting in mRNA translation
arrest and blocking of protein expression [8]. A third
mechanism involves the hybridization of an AON to in-
tronic/exonic inclusion sequences of primary RNA tran-
scripts, thus rendering specific exons inaccessible to the
splicing machinery and leading to skipping of the exon
[9]. In a similar fashion, AONs can hybridize to intronic/
exonic exon exclusion sequences and result in inclusion of
target exons [7,10].
To date, modulation of splicing by AONs has been
used as a potential treatment approach for several dis-
eases, including Duchenne muscular dystrophy (DMD)
and models of spinal muscular atrophy (SMA) [10-12].
Effective protein restoration in DMD via exon skipping
has been shown in patient derived cell cultures, animal
models, (reviewed in [9] and even in clinical trials [13,14].
Similar results have been obtained in SMA via the related
mechanism of exon inclusion [10,15-17].
Despite the potential of splicing modulation, AONs have
been used in an experimental setting mainly to induce
knockdown of gene expression [18-20], while antisense-
mediated modulation of splicing has not been used widely
as a research tool in the brain. One of the obstacles pre-
venting their more widespread application in the central
nervous system (CNS) is their inability to cross the blood-
brain-barrier of adult animals [21]. Nevertheless, when
AONs are applied directly to the CNS via intracerebro-
ventricular (ICV) or intrathecal administration, the results
show considerable potential [10,12,21] and long-lasting
effects [10,21]. In this study we evaluated the efficacy and
occurrence of immune-related side effects after a single
local AON injection in the central amygdala of the mouse
brain. As proof of principle, we targeted steroid receptor
coactivator-1 (SRC-1), a gene that codes for two splice
variants, SRC-1a and SRC-1e, which only differ in one
exon (Figure 1; [22,23]). SRC-1 can act as a coregulator of
glucocorticoid receptor (GR) dependent transcription
[24], as well as of other nuclear receptors [25]. The SRC-1
splice variants show differential activity and distribution in
the brain [26]. The splice variants have been shown to
exert opposite effects on the GR-mediated regulation of
the crh gene [27].
We targeted exon 22 of the SRC-1 gene (Figure 1)
using AONs, examined their cellular uptake by different
cell types, exon skipping efficacy over time and potential
Figure 1 Schematic representation of the mRNA of the two SRC-1 splice variants. Boxes represent exons and thicker full lines represent
introns. Dashed lines indicate possible splicing events. The approximate position of stop codons is also marked. If exon 22 is included, SRC-1e is
expressed. Exon 22 contains an earlier stop codon, therefore SRC-1e protein is shorter than SRC-1a. AONs targeting exon 22 can render it
inaccessible to the splicing machinery and therefore, shift the expression of SRC-1 towards SRC-1a. (Adapted from Kalkhoven et al. [23]).
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immunostimulatory effects. For cellular uptake and po-
tential immunostimulatory effects we used an AON tar-
geting human dystrophin that has no known targets in
the murine genome, in order to investigate the target-
independent physico-chemical properties of 2-O’-methyl
modified phosphorothioate oligonucleotides. Our results
showed adequate uptake by cells in the CeA and trans-
location into the cell nucleus, combined with detectable
isoform switching until at least 7 days after a single in-
jection and a practically complete lack of immunostimu-
latory effects compared with vehicle injection.
Results
Cellular uptake
In order to investigate the cell types and intracellular
destination of 2-O’-Methyl phosphorothioate AONs we
performed immunofluorescent detection of CRH (which
is expressed in the CeA), NeuN and Hoechst after local
injection of an AON targeting human dystrophin, which
has no known targets in the mouse. Our results showed
that fluorescently labeled AONs were taken up by neu-
rons in general, as well as neurons expressing CRH in
the CeA, and also translocated into the cell nucleus
(Figure 2A-D). Quantification showed that 67.5% ± 2.6
of the cells that had taken up the AONs was NeuN posi-
tive. This indicates that the AONs can indeed be taken
up by neurons in the brain and translocate to the nu-
cleus where splicing events take place.
AON detection
In order to determine the stability of AONs in the
brain after local injection we measured the intensity
of the green fluorescence originating from the fluo-
rophore conjugated to AONs in the brains of animals
sacrificed 1, 3, 5, 7 and 14 days after a single in-
jection with an AON targeting human dystrophin.
Figure 2 AON uptake by different cell types and nuclear localization in the central amygdala (CeA). A. Uptake of AONs by neurons. The
green fluorescence of the labeled AONs is colocalized with NeuN (red), a marker of neurons. Scale bar 50 μm B. Uptake of AONs by cells
expressing CRH. AONs (green) are located in the nuclei of those cells (white arrowheads), surrounded by CRH in the cytoplasm (red). Scale bar
15 μm. C, D. Localization of AONs (green) in the cell nucleus, colocalized with the nuclear marker Hoechst (blue). Scale bar 50 μm. The area
within the red square is magnified in D (scale bar 15 μm). E. Fluorescent intensity in the cell nuclei after an injection of AONs. Fluorescence on
day 1 was normalized to 100%. One-way ANOVA (F(4,14)= 7.845, p<0.01) followed by Dunnett’s post hoc test (all groups compared to the 1 day
group) showed a significant decrease of fluorescence after 7 and 14 days (Dunnett’s test p<0.05 in both cases). Between the 7- and 14-day
groups there was no further decrease. F. Uptake of AONs (green) by GFAP (red) positive astrocytes. Several astrocytes have taken up AONs while
others have not. White arrowheads indicate a few examples of astrocytes that took up AONs, whereas blue arrowheads indicate a few examples
of those that did not. Scale bar 30 μm.
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Fluorescence intensity did not differ significantly be-
tween 1 and 3 days but subsequently decreased over
time to less than 50% in 7 days (Figure 2E). After 7
days, fluorescence intensity remained stable until the
last detection time point, 14 days post-injection. In
these calculations only green signal colocalized with
Hoechst (cell nuclei) was taken into account, thus
restricting our analysis to a functionally relevant sub-
cellular compartment.
Diffusion of AONs
In order to investigate the specific targeting of a selected
brain region we measured the diffusion of the AONs
around the injection site. Our results indicated a well
localized targeting of about 0.1 mm3 (Table 1).
Immunostimulatory effects
We analyzed two different markers for microglia activa-
tion (CD-45 and IBA1) and one marker for astrocytes
(GFAP). CD-45 is a marker of activated microglia, whereas
IBA-1 is a constitutive marker of microglia [28,29]. We
compared AON-injected (with an AON targeting human
dystrophin) to saline-injected animals 3 and 7 days after
the injections. Moreover, we included an untreated group
of animals to assess the effects of the injections. No differ-
ences were observed between saline and AON treated ani-
mals at either time point (Figures 3,4). AON uptake was
also observed in a subset of GFAP positive astrocytes
(Figure 2F). Little or no uptake by microglia was observed.
Isoform switching
In order to determine the efficacy of AONs treatment on
exon skipping in the brain we used qPCR analysis to meas-
ure the expression ratio of the two isoforms in the CeA, 3
and 7 days after a single injection with either an AON
against SRC-1e or a control-AON. Three days after the in-
jection the SRC-1a:SRC-1e ratio showed a 2-fold shift in
favor of SRC-1a in the group injected with AONs against
SRC-1e, in comparison to the control-AON injected group.
However, total SRC-1 expression was not different between
the groups (Figure 5). Seven days after injection the expres-
sion ratio was still significantly higher in the animals
injected with AONs against SRC-1e (approximately 1.5-
fold higher than their control injected counterparts) with-
out a difference in total SRC-1 expression. As an additional
control for specificity, mRNA for GR (which may be one of
the target nuclear receptors of SRC-1) was not significantly
different between the groups either at the 3- or the 7-days
time point. In view of previously reported upregulation
of SRC-2 in SRC-1 knockout mice [30], we determined
SRC-2 mRNA. We did not find a significant difference
between the two groups regarding SRC-2 expression 3
days post injection. SRC-2 expression was 0.7 ± 0.2 for
animals injected with AONs targeting SRC-1e and 1.0 ±
0.3 for animals injected with human dystrophin (inde-
pendent t-test, t(6)=0.8511, p>0.42).
Discussion
In this study, we investigated the efficacy in AON-mediated
isoform switching, AON uptake by different cellular types
and the putative immunostimulatory effects of AONs, in
order to evaluate their potential use as a tool in experimen-
tal brain research.
Our results showed that it is possible to alter the ex-
pression ratio of the two SRC-1 isoforms with a single
injection of AONs targeting exon 22 of the transcript of
SRC-1e. Three days after the injection the isoform ex-
pression ratio showed a 2-fold increase in favor of
SRC-1a, whereas 7 days after a single injection of AONs
the respective difference was approximately 1.5-fold in
favor of SRC-1a. In order to confirm that this was a
genuine effect and was not influenced by downregulation
of total SRC-1 we also investigated total SRC-1 expres-
sion in the two groups, which was shown to be compar-
able and not significantly different at both time points.
We also investigated the expression of GR to control for
possible differences as a consequence of off-target non-
homologous binding of the AONs. We selected GR as an
additional control, because SRC-1 is involved in GR-
dependent pathways. Our results showed that GR mRNA
expression is not significantly different between animals
injected with either an AON targeting SRC-1e or a control
AON 3 or 7 days after a single injection. This finding indi-
cates no difference in non-homologous targeting between
the specifically targeted and the control AONs and is also
relevant for future experiments attempting to unravel the
role of SRC-1 and its isoforms in GR dependent pathways
as any effects can be attributed solely to SRC-1 isoform
switching. Since SRC-2 has been shown to be upregulated
in the absence of SRC-1 during development [30], we
investigated its expression 3 days after injection in order
to rule out an effect of SRC-1 isoform switching on SRC-2
expression. We did not find SRC-2 upregulation, which is
in line with the absence of effects on total SRC-1. Al-
though a larger-scale transcriptome and/or proteome
analysis would be necessary to investigate all potential off-
Table 1 Diffusion of the AONs in the brain in the
mediolateral, dorsoventral and anterior-posterior axes
Measurement Size SEM
Mean mediolateral diffusion 505 70
Mean dorsoventral diffusion 671 84
Mean anterior-posterior diffusion 350 34
Maximum mediolateral diffusion 903 -
Maximum dorsoventral diffusion 1015 -
Mean Volume 0.11 0.03
Lengths in μm, volumes in mm3. Data shown as mean ± SEM.
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target effects of the AONs used in this study [31], our
results from total SRC-1, SRC-2 and GR mRNA expres-
sion indicate high specificity. In addition, since AONs do
not obligatorily interfere with endogenous pathways, un-
like siRNAs, they cannot saturate the cellular miRNA ma-
chinery [21], thus avoiding a source of off-target effects.
Regarding the effect size of the AONs’ efficacy, it is
important to note that the dissected area, particularly at
longer distances from the injection site may contain cells
that did not take up AONs. For the group treated with
AONs against SRC-1e that would mean a dilution of the
effect. Therefore, the actual efficacy of exon skipping
could well be higher than observed.
The detection of isoform switching 7 days after a sin-
gle injection of AONs allows animals sufficient time for
post-operational recovery and performance of additional
experiments, for instance, behavioral experiments. In
addition, we were able to detect fluorescence of AONs
up to 14 days after injection, which is probably accom-
panied by isoform switching to some extent, although
the decrease of the expression ratio of the two isoforms
between 3 and 7 days indicates that the effect size may
decrease over time. If longer lasting effects are required,
potential solutions may involve higher doses and repeated
or continuous administration [21]. Persisting effects have
been shown even 6 months after termination of continu-
ous infusion of AONs for 7 days in the ventricles of the
brain [10], and even single administration may have long-
lasting effects [32].
Astrocytosis and microglia activation may confound any
findings in relation to brain function. We found no differ-
ences in the immune responses caused by a single injec-
tion of AONs or a single injection of sterile saline 3 or 7
days after the injections. The time course of astrocytosis
and microgliosis that we observed both in vehicle and
AON treated animals was similar to what has been previ-
ously reported for saline injections [29]. It is unlikely we
have reached a plateau in immune responses with saline,
since it has been shown in the past that administration of
lipopolysaccharide causes substantially stronger immune
responses than saline [29]. Immunostimulatory effects that
have been observed in other studies may have been caused
Figure 3 GFAP immunoreactivity 3 or 7 days after a single injection in the CeA. A. 3 days after a single saline injection. B. 7 days after a
single saline injection. C. 3 days after a single injection of AONs. D. 7 days after a single injection of AONs. E. GFAP immunoreactivity in the CeA
of an untreated mouse. F. Quantification of GFAP immunoreactive area shown as percentage of the total area of visual field. One-way ANOVA
followed by Tukey’s post hoc test revealed no significant differences between the respective AON and saline injected animals (one-way ANOVA
F(4,17)=1.266, p>0.32, N=3-7 animals per group). In conclusion, a single AON injection did not induce stronger astrocytosis than saline. Scale bar
50 μm. Red: GFAP, blue: Hoechst. Green signal (AONs) has been omitted for clarity.
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by the vehicle used [33], or immune responses elicited by
simulation of Toll-Like receptors (TLRs) through the
phosphorothioate backbone of the AONs [34]. However,
2-O’-modifications may act as TLR antagonists [35],
which may account for the lack of immune responses in
our study (in spite of the high local concentrations of
AONs), as well as in others [21]. Hua et al., 2010 reported
an upregulation of IBA-1 mRNA expression after continu-
ous infusion for 9 days of 2-O’-Methyl modified AONs
but not of 2-O’-Methoxyethyl AONs compared to saline.
This discrepancy between the current study and the study
of Hua et al. may be due to the different experimental
setup. The current study used a local single injection of
~1 μg of AONs instead of a continuous ICV administra-
tion of 10 μg or more per day for 9 days that induced sig-
nificant upregulation of IBA-1 in the spinal cord, or 30 μg
or more that was necessary to induce significant upregula-
tion of IBA-1 in the brain. Administration of 10 μg of
AONs per day was not enough to cause significant IBA-1
upregulation in the brain. Although it is difficult to
compare final local concentrations of the two approaches,
our results show that we probably remain well within the
“safe” range regarding the induction of immune responses.
Nevertheless, this indicates that side effects of AON treat-
ment may also depend on design, dose, frequency or deliv-
ery of treatment and one should be aware of potential
risks [7].
Before AONs can exert their effect, it is crucial that
they cross the cell membrane and the nuclear mem-
brane, since splicing takes place in the nucleus [36].
How AONs are taken up and how they are transported
to the nucleus is not known. It has been shown in mod-
els of DMD that because of the lack of dystrophin pro-
tein, affected muscle cells can more easily take up AONs
due to the altered properties of their muscle fiber mem-
branes and a more open endothelium [37]. However,
mechanisms of AON uptake by intact neurons in the CNS
are probably different and may involve utilization of traf-
ficking pathways for cellular uptake of AONs including
absorptive endocytosis, pinocytosis and clathrin-,
Figure 4 CD-45 immunoreactivity 3 or 7 days after a single injection in the CeA. A. 3 days after a single saline injection. B. 7 days after a
single saline injection. C. 3 days after a single injection of AONs. D. 7 days after a single injection of AONs. E. CD-45 immunoreactivity in the CeA
of an untreated mouse. F. Quantification of CD-45 immunoreactive area shown as percentage of the total area of visual field. One-way ANOVA
followed by Tukey’s post hoc test revealed no significant differences between the respective AON and saline injected animals (one-way ANOVA
F(4,17)=1.092, p>0.39, N=3-7 animals per group). Quantification of IBA-1 immunoreactive area had similar results (one-way ANOVA F(4,17)=1.535,
p>0.23, data not shown). In conclusion, a single AON injection did not induce stronger microglia activation than saline. Scale bar 50 μm. Red:
CD-45, blue: Hoechst. Green signal (AONs) has been omitted for clarity.
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caveolin-, actin-, dynamin- dependent and -independent
pathways [36,38-40]. Moreover, AON cellular uptake
may exploit the natural pathways of cell-to-cell nucleic
acid transportation that may be also involved in micro-
RNA transportation [41]. It is very likely that different
physical and chemical properties of AONs depending
on their chemistry, 2-O’-modifications and length may
also be determining factors for the manner and effi-
ciency of uptake [42]. The AON chemistry used in the
current study has been shown to be advantageous for
nuclear uptake [43].
We also showed that cells of interest in the CeA can
take up AONs; NeuN and CRH positive cells represent
neurons and cells expressing CRH, a hormone crucial
for fear conditioning and orchestration of stress responses
in the brain [44], and a putative target of SRC-1 mediated
regulation [45]. NeuN positive cells account for the major-
ity of cells taking up AONs. Moreover, we observed
sporadic AON uptake by astrocytes and little or no by
microglia. The low uptake by microglia cells may be due
to either the properties of those cells, or the fact that they
seem to arrive at the injection site probably after AONs
have been already taken up by other cells. The fraction of
AON-positive astrocytes was substantially lower than for
NeuN-positive cells. Other studies suggested that in pri-
mates AON uptake by astrocytes may be more substantial
[21]. On the other hand, GFAP staining visualizes only
part of the total population of astrocytes [46] since some
astrocytes do not express GFAP [47]. Hence, it is possible
that GFAP negative astrocytes may have taken up AONs.
To summarize, based on our findings we can conclude
that generally neurons in the brain take up AONs,
Figure 5 qPCR analysis of gene expression 3 or 7 days after a single injection. A. Relative expression of the SRC-a1/SRC-1e 3 ratio days after
a single injection of AONs. AON treatment targeting exon 22 of SRC-1e leads to a 2-fold difference of the expression ratio of the two isoforms in
favour of SRC-1a (independent t-test, t(6)=2.414, p<0.05, n=6-7 per group). B. Relative expression of the SRC-1a/SRC-1e ratio 7 days after a single
injection of AONs. AON treatment targeting exon 22 of SRC-1e lead to 1.5-fold difference of the expression ratio of the two isoforms in favour of
SRC-1a (independent t-test t(8)=2.420, p<0.05, n=5 per group). C, D. Treatment with AON targeting exon-22 of SRC-1e had no effect on total SRC-
1 expression compared to control 3 (C) or 7 days (D) after a single injection (independent t-tests, t(11)=0.006, p>0.99 and t(7)=1.304, p>0.57
respectively, n=4-7 per group). E, F. GR expression remained unchanged between animals injected with AON targeting exon 22 of SRC-1e and
controls 3 (E) or 7 days (F) after a single injection (independent t-tests, t(11)=0.479 p>0.64 and t(7)=0.662, p>0.52, n=4-7 per group).
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without, however, being able to rule out the possibility
that different populations of neurons may display uptake
at different rates, efficiencies or even complete lack of
AON uptake. In the injected areas in the CeA, though, the
vast majority of NeuN positive cells take up AONs.
It is important to mention that we did not detect the
AONs directly, but rather the fluorophore with which
they were labeled. Since this can be cleaved off, it would
be possible that we detected fluorophores that were not
bound to the AONs. However, that is not likely since
uptake takes place very rapidly after injections, when lit-
tle or no degradation of the AON-fluorophore complex
is expected. Moreover, the considerable effect on exon
skipping 3 and 7 days after an injection indicates AON
activity which coincides with detection of fluorescence
in the cells. For this study we made the assumption of
equal stability between the two AONs.
Although the addition of a fluorophore increases hydro-
phobicity, hence cellular trafficking, it also increases its
size. Therefore, the diffusion we observe here might be an
over- or an underestimation of what it would be without
the fluorophore attached. Importantly, efficacy has been
shown to be similar between labeled and unlabeled AONs
[48,49]. Finally, our measurements of the diffusion of the
AONs indicate that a specific brain region can be targeted
with minimal leakage to adjacent areas. The diffusion
observed here is likely a function of the targeted area, the
volume and AON concentration and the injection rate
and it may not be possible to directly extrapolate to other
situations. Nevertheless, one would assume that with an
optimal combination of volume and concentration smaller
regions may also be targeted with reasonable specificity.
Conclusions
In conclusion, we have shown that it is possible to in-
duce specific exon skipping and subsequent isoform
switching of SRC-1 in the CeA without noticeable ad-
verse effects. Our future work will address the functional
consequences of SRC-1 isoform switching, as well as the
many additional genes that are potential targets of such.
This use of isoform switching with AONs has great po-
tential that it must be considered not only in cases where
it can restore aberrant gene expression and function, but
also as an important molecular tool for manipulation of
gene expression that constitutes an alternative to RNA
interference or knock-out models.
Methods
Animals, stereotactic surgery and tissue processing
C57bl/6j male mice between the ages of 12-14 weeks
(Janvier SAS, France) were used for all experiments. Ani-
mals were singly housed in individually ventilated cages at
a 12 hour light cycle with lights on at 7 am. Food and
water were available ad libitum. All animal experiments
were carried out in accordance with European Communi-
ties Council Directive 86/609/EEC and the Dutch law on
animal experiments and were approved by the Leiden
University animal ethical committee (protocol number:
10128). Animals were anesthetized with a cocktail of
Hypnorm-Dormicum-demineralized water in a volume
ratio of 1.33:1:3. The depth of anesthesia was always con-
firmed by examining the paw and tail reflexes. When mice
were deeply anesthetized they were mounted on a Kopf
stereotact (David Kopf instruments, Tujunga, CA, USA).
For every experiment, animals were bilaterally injected with
0.5 μl of the appropriate solution (sterile saline, AONs at a
concentration of 400 pmol/μl in sterile saline (Eurogentec,
Liège, Belgium)) in the central amygdala (coordinates rela-
tive to bregma: -1.25 mm anterior-posterior, ±2.95 mm
medio-lateral and -4.75 mm dorso-ventral) [50]. For injec-
tions, customized borosilicate glass micro-capillary tips of
approximately 100 μm in diameter, connected to a Hamil-
ton needle (5 μl, 30 gauge) were used. The Hamilton syr-
inge was connected to an injection pump (Harvard
apparatus, Holliston, MA, USA) which controlled the in-
jection rate set at 0.15 μl/min. After surgery the animals
were returned to the home cage and remained undisturbed
until sacrifice, with the exception of daily weighing in order
to monitor their recovery from surgery. To assess mRNA
expression, animals were decapitated after an intraperito-
neal injection (i.p.) of overdose Euthasol (ASTfarma, Oude-
water, the Netherlands), brains were removed quickly and
snap frozen on dry ice. For detection of the presence of
AONs over time and putative immunostimulatory effects,
mice were sacrificed with transcardial perfusion with a so-
lution of 4% paraformaldehyde (PFA) (Sigma-Aldrich,
Zwijndrecht, the Netherlands) in 0.1 M phosphate buffer
saline (PBS) after an i.p. injection of overdose Euthasol, 1,
3, 5, 7 and 14 days after the injection. Each time point con-
tained 3-7 animals. In order to assess potential immunosti-
mulatory effects we used animals injected with 0.5 μl
sterile saline (vehicle) that were sacrificed either 3 or 7 days
(4 per group) after the injection as controls for the respec-
tive time points. Three additional animals were sacrificed
without having been operated on. After sacrificing the ani-
mals, the brains were removed and postfixated overnight in
4% PFA at 4°C. Subsequently they were cryoprotected in
15% and 30% sucrose, snap frozen on dry ice and stored at
-80°C.
Antisense oligonucleotides
Two different green fluorophore labeled AONs were used:
one targeting human dystrophin, which has no known
targets in the mouse (CGCCGCCAUUUCUCAACAG), la-
beled with a fluorescein amidite (FAM) fluorophore and
one targeting exon 22 of SRC-1, that is specific for the
SRC-1e splice variant (CUGUAGUCACCACAGAGAAG),
labeled with Alexa FluorW 488. The AON against exon 22
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of SRC-1e was administered in order to investigate
whether it can induce exon skipping, whereas the AON
against human dystrophin was used as control to study cel-
lular uptake and potential immunostimulatory effects.
AONs were modified with a full-length phosphorothioate
backbone which increases AON stability and cellular up-
take and consisted of 2-O’-methyl RNA to render them
RNase H resistant and to counterbalance potential immu-
nostimulatory effects caused by the phosphorothioate
modified backbone [34,35,51,52].
Immunofluorescence
Brains were sectioned at a thickness of 25 μm on a Leica
cryostat and sections stored in antifreeze solution [30%
ethylene glycol (Merck, Darmstadt, Germany), 20% gly-
cerol (Sigma-Aldrich), 0.02 M Na2HPO4 (Merck), 6.6 mM
NaH2PO4 (merck)] at -20°C until use. Before use sections
were washed in PBS to remove anti-freeze. Subsequently
sections were incubated in 0.5% triton X-100 (Sigma-
Aldrich) in PBS for 30 min to increase permeability of the
cells and washed with PBS. Blocking with 2% normal
donkey serum (Brunschwig Chemie, Amsterdam, the
Netherlands) in PBS-BTSA for 45 min was followed by an
overnight incubation with primary antibody at room
temperature (Table 2). Afterwards, the primary antibody
was washed out with PBS and incubation with the second-
ary antibody (Table 2) followed for 2.5-3 h. The secondary
antibody was washed followed by 10 min incubation with
Hoechst (1:10000) (Hoechst 33258, pentahydrate, bis-ben-
zymide, Invitrogen, Breda, the Netherlands) and another
PBS washing step. Finally, the sections were mounted on
glass slides, dried and coverslipped with Aqua Polymount
(Polysciences Inc, Eppelheim, Germany). Slides were
stored at 4°C until observation.
Microscopy
Confocal imaging was performed on a Nikon Eclipse
TE 200-E microscope. Confocal images were collected
as z-stacks at a magnification of 200 or 600 times with a
z step size of 0.5 μm and an image size of 1024×1024
pixels. When two or more markers were determined in a
single section, the different channels were imaged separ-
ately to avoid artifacts due to overlap of the emission
wavelengths of the fluorescent labels. The same settings
were used to obtain images for quantification (e.g. at dif-
ferent time points, between subjects or between groups
for the same marker). Z-stacks were converted to .avi for-
mat and then stored as single image .tiff files using the z-
projection function of Image J (NIH, Bethesda, MD) with
standard deviation as projection type. Images of damaged
sections or images with artifacts were excluded from fur-
ther analysis. Finally, to examine cellular uptake and
colocalization of different markers we merged different
channels of the same image in Image J.
Image processing
Appropriate thresholds were applied to correct for back-
ground. For each marker the positive stained area was
presented as a percentage of the total area of the visual
field. In order to reduce measurement bias, holes or rup-
tures in the tissue were not taken into account for the
calculation of total area. For determination of immune
responses 3-4 pictures were used per brain and the
mean value of those was used as the sample value.
Diffusion of the AONs
For determination of the diffusion of the AONs in the
brain we measured the diffusion of the green fluorescence
in the medio-lateral axis and the dorso-ventral axis in
Image J on 4 or 5 10 μm-thick sections per brain (n=6)
which were taken 80 μm apart from each other. Images
were taken on a Nikon eclipse 6800 fluorescent micro-
scope at 100X magnification. Before measurements, ap-
propriate background correction was applied. Lines were
drawn along the medio-lateral and dorso-ventral axes and
their length was measured in pixels. With help of a cali-
bration slide we converted the values from pixels to μm.
The positive area for green fluorescence was also mea-
sured and total positive volume was calculated according
Table 2 Antibodies and dilutions used for all immunofluorescent stainings
Primary antibodies Secondary antibodies
Marker Type Manufacturer Dilution Type Manufacturer Dilution
CRH Goat polyclonal Santa Cruz biotechnology,
Heidelberg, Germany
1:250 Donkey anti-goat Invitrogen, Breda,
the Netherlands
1:100
NeuN Mouse monoclonal Chemicon, Amsterdam, the Netherlands 1:200 Donkey anti-mouse Invitrogen, Breda,
the Netherlands
1:500
GFAP Mouse monoclonal Santa Cruz biotechnology,
Heidelberg, Germany
1:1000 Donkey anti-mouse Invitrogen, Breda,
the Netherlands
1:500
IBA-1 Goat monoclonal Santa Cruz biotechnology,
Heidelberg, Germany
1:200 Donkey anti-goat Invitrogen, Breda,
the Netherlands
1:400
CD-45 Rat polyclonal Serotec, Düsseldorf, Germany 1:1000 Donkey anti-rat Invitrogen, Breda,
the Netherlands
1:500
The fluorophore of all secondary antibodies was Alexa FluorW 594.
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to Cavalieri’s rule. Mean and maximum diffusion distances
were calculated as well as total volume per sample.
Laser microdissection and RNA processing
Cryosections at a thickness of 10 μm were taken from
snap frozen brains and mounted on polyethylene naphtha-
late membrane slides (Carl Zeiss, Munich, Germany). Up
to 5 sections were mounted on a slide with adjacent sec-
tions being on different slides. The slides were stored at
-80°C until laser microdissection. Laser microdissection
was carried out on a Palm laser microdissection micro-
scope as has been described elsewhere [53,54]. Briefly, sec-
tions were observed under fluorescent light in order to
determine regions that had taken up AONs. With the as-
sistance of appropriate software the desired regions were
selected, microdissected and collected in adhesive caps
(Carl Zeiss). Collected tissue was then stored in Trizol
(Invitrogen) at 4°C until RNA isolation, which was always
carried out the same day as laser microdissection in order
to preserve RNA quality. RNA isolation was performed as
has been described elsewhere [55]. Briefly, RNA was iso-
lated with chloroform and precipitated with isopropanol
and linear acrylamide. RNA pellets were rinsed with ice
cold ethanol 75%, air-dried and resuspended with RNase-
free DEPC-treated demineralized water. Quality and
concentration of RNA samples were measured on a Bioa-
nalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA) using the RNA 600 Pico LabChip according to the
manufacturer’s instructions.
cDNA synthesis
RNA samples were first treated with DNAse I (Invitro-
gen) to remove potential genomic DNA contamination.
Subsequently, RNA samples were reverse transcribed
with iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA). Briefly, 4 μl of 5 times iScript reaction mix, 1 μl
of iScript reverse transcriptase and 5 μl of Nuclease-free
H2O were added to 10 μl of DNase I treated RNA. Sub-
sequently samples were incubated for 5 min at 25°C fol-
lowed by 30 min at 40°C and finally 5 min at 85°C in a
PTC-200 DNA engine cycler (Bio-Rad).
qPCR
Quantitative polymerase chain reaction (qPCR) was per-
formed for assessment of gene expression in the CeA of
AON injected mice. A 1:1 dilution of cDNA in autoclaved
demineralized water was used for qPCR. The quantifica-
tion of cDNA was performed on a LightCycler 2.0 (Roche
Applied Science, Basel, Switzerland) using LC FastStartDNA
MasterPLUS SYBR Green I (Roche). 2.5 μl of cDNA was
added to a mix of 2 μl 5 times Sybr green mix, 1 μl of
both forward and reverse primers (5 μM) and 3.5 μl
nuclease-free water, in LightCycler Capillaries (20 μl,
Roche). All measurements were performed in duplicate.
The PCR program comprised 10 min at 95°C followed
by 45 cycles of denaturation at 95°C for 10 sec, anneal-
ing at 60°C for 10 sec and elongation at 72°C for 10
sec, with a subsequent dissociation stage (from 65°C to
95°C, at a rate of 0.1°C/sec). The SRC-1 splice variants
were quantified as an expression ratio of SRC-1a/SRC-1e;
the expression of total SRC-1 and GR was normalized
against β-actin. Quantification of relative expression
was calculated using the Pfaffl method [56] and nor-
malized against the control group (dystrophin AON).
The forward and reverse primers used for the different
genes were respectively: 50-CCTCTACTGCAACCAGC
TCTCGTC-30 and 50-TGCTGCACCTGCTGGTTTCC
AT-30 for SRC-1a; 50-TGCAACCAGCTCTCGTCCAC
TG-30 and 50-GCTCCTCTAGTCTGTAGTCACCACA-30
for SRC-1e; 50-CGACCGCAGAGCAGCAGTTA-30 and
50-GCCGCTCAGTCAGAGAGCTG-30 for total SRC-1;
50-CCCTCCCATCTAACCATCCT-30 and 50-ACATAAG
CGCCACCTTTCTG-30 for GR; 50-TTTCCCACAGCAG
TACGCAT-30 and 50-TAATTTGGCCGCTGTCCCAT-30
for SRC-2; 50-CAACGAGCGGTTCCGATG-30 and 50-
GCCACAGGATTCCATACCCA-30 for β-actin.
Statistical analysis
For comparisons between two groups an independent
t-test was used. For comparisons among multiple groups
one-way ANOVA was used followed by Tukey’s post-hoc
test (for comparison of immunostimulatory effects be-
tween all groups) or Dunnett’s post-hoc test (for com-
parison of fluorescence intensity at different time points
with fluorescence intensity after one day post-injection).
All data are presented as mean ± SEM.
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